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Abstract
Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast and ovarian 
cancer that are so high and seem so selective that many mutation carriers choose to have prophy-
lactic surgery.   There has been much conjecture to explain such apparently striking tissue specific-
ity.  All these suggestions share the assumption that some disabled function of normal tumor sup-
pressor genes leads to a tissue specific cancer response.  Here the idea is proposed and tested that 
major determinants of where BRCA1/2 hereditary cancers occur are related to tissue specificity of 
the cancer pathogen, the agent that causes chronic inflammation or the carcinogen.  The target tis-
sue may have receptors for the pathogen, become selectively exposed to an inflammatory process 
or to a carcinogen such as during digestion, metabolism or elimination.  An innate genomic deficit in 
a tumor suppressor gene impairs normal responses to these extrinsic challenges and exacerbates 
the susceptibility to disease in organ targets.  This hypothesis also fits data for several tumor sup-
pressors beyond BRCA1/2.  A major advantage of this model is that it suggests there may be some 
options in addition to prophylactic surgery.
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Abbreviations
A-T, ataxia-telangiectasia;  ATM, gene mutated in ataxia-telangiectasia; CI, confidence interval; DSB, 
DNA double strand break; EBV, Epstein-Barr virus; FA, Fanconi anemia; HBV, hepatitis B virus;    
HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus; DCIS, ductal carci-
noma in situ;  HR, hazard ratio; I2, inconsistency statistic; MMTV, mouse mammary tumor virus; NK 
cells, natural killer cells; NSAIDs, non-steroidal anti-inflammatory drugs; OC, oral contraceptives; 
OR, odds ratio; RR, relative risk.
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Introduction
Women who inherit a defective BRCA1 or 
BRCA2 gene have risks for breast / ovarian cancer 
that are so high and apparently so selective that many 
mutation carriers choose to have prophylactic sur-
gery. Rebbeck et al. (2009), King et al. (2003).   This 
raises the question why cancer just attacks breasts 
and ovaries when every cell with a nucleus inherits 
the same mutation.  Functionally, both BRCA genes 
are general cell requirements because they encode 
products essential for fundamental activities such as 
DNA repair.   Why does inheriting a defect in general 
cell requirements lead to cancers in specific target 
organs?  Answering these questions might help delay 
or prevent the onset of hereditary cancers.  
One plausible explanation involves the high 
proliferative activity in ovary and breast tissues, espe-
cially when under the influence of estrogens.  (Welcsh 
and King, 2001).  Cells with an inherited deficit in 
BRCA1 or BRCA2 acquire a second mutation spon-
taneously in these tissues.  Mutations in BRCA1 and 
BRCA2 genes may be more likely because of high 
frequencies of repetitive elements.  (Welcsh and King, 
2001).   Cells with mutations in both alleles then 
become repair deficient and acquire additional muta-
tions even more readily.  Tumors of BRCA1/2 carri-
ers have more losses and gains than non-hereditary 
cancers.  Jonsson et al. (2005), Joose et al. (2009).  
Most grossly abnormal cells die, but in rapidly prolif-
erating breast epithelium some abnormal cells escape 
by acquiring critical checkpoint mutations.  These cells 
may give rise to cancers.   One objection to this ex-
planation is that other tissues and cells also have high 
proliferation rates but are not generally regarded as 
specific sites for tumor formation in BRCA1/2 muta-
tion carriers.   However, implicating BRCA1/2 and 
associated genes in lymphomas and leukemias does 
suggest that prolonged high proliferation rates may 
contribute (Friedenson, 2007).  
The predilection of BRCA1 carriers to de-
velop cancers in breast and ovary suggests tissue 
specific activities that may be due in part to tissue 
specific transcription functions.  While it has not been 
demonstrated that BRCA1 can interact directly with 
a sequence within undamaged DNA, BRCA1 can bind 
to various sequence-specific DNA binding transcrip-
tion factors to alter transcription. Rosen et al. (2006). 
It is possible that BRCA1 may regulate certain genes 
expressed only in the breast and ovaries.  The al-
tered expression of these transcripts would lead to 
an increase in neoplastic transformation. (Welcsh 
and King, 2001).   However, risks for other cancers in 
organs beyond breast and ovary are increased as well, 
especially in children born with biallelic mutations in 
BRCA2.  Alter et al. (2007)
A major biochemical consequence of BRCA1 
deficiency is the loss of functional complexes between 
BRCA1- and BRCA1-interacting proteins. BRCA1 
contains several functional regions that interact with 
proteins including ATM, p53, RB, c-Myc, BRCA2, DNA 
repair factors, E2F, and others.  Many of these are pro-
to-oncogenes or tumor suppressors that can regulate 
transcription through both direct and indirect mecha-
nisms. However, none of these BRCA1 interacting 
proteins show a tissue restricted pattern of expres-
sion that could explain the specific tissue tropism of 
BRCA1-related cancers. (Gardner and Liu, 2001)
According to another conjecture, ovary- and 
breast-specific BRCA1 cofactors could cause trans-
formation in the absence of BRCA1.   The presence of 
hormonal survival factors may have a protective effect, 
allowing cells with inactive BRCA1/2 to survive and 
proliferate. Both the breast and ovaries are targets of 
estrogen and other hormones that endow anti-apop-
totic survival functions. (Gompel et al. 2000).  BRCA1 
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may play an inhibitory role in estrogen receptor (ER) 
signaling that could help explain the tissue specificity. 
Fan et al. (2001), (Dizin and Imminger-Finger, 2010).   
However, most BRCA1 associated tumors lack ER 
expression and it is still unclear if such tumors arise 
from cells that never expressed ER or that subse-
quently lost ER expression.  Tamoxifen use beginning 
at age 35 years or older did not reduce breast can-
cer incidence among healthy women with inherited 
BRCA1 mutations. Tamoxifen reduced ER positive 
breast cancer incidence among healthy BRCA2 carri-
ers by about the same amount as in normal women. 
King et al. (2001)
This does not rule out some hormonal ef-
fects.  In a prostate cancer model, hormone receptor 
complexes move regions of chromosomes into close 
proximity and increase risks for site specific cancer 
related gene fusions after DNA double strand breaks 
are induced by DNA radiation damage. Lin et al. 
(2009)   
BRCA1 and BRCA2 gene products interact 
with recombination / DNA repair proteins in path-
ways that participate in preserving intact chromo-
some structure.  It is unclear to what extent such 
functions specifically suppress breast and ovarian 
cancer (Scully and Livingston 2000).  It is possible that 
impaired DNA repair processes themselves trigger 
cancer by allowing mutations to accumulate.  This 
does not account for why cancer occurs in some tis-
sues but not others.   
Zhou and Elledge suggested that most tis-
sues have alternative ways of performing BRCA1 or 
BRCA2 tumor suppressing functions but breast and 
ovary do not.  Therefore, loss of normal BRCA1/2 
proteins in tissues with alternate mechanisms has 
less effect.  BRCA2 again challenges this conjecture 
because people survive with bi-allelic mutations in 
BRCA2.  Thus every cell is capable of surviving with 
inactivated BRCA2.  Zhou and Elledge (2002) pro-
posed that BRCA1 and BRCA2 (like other tumor 
suppressors) acquire specificity by exploiting unique 
properties of their target tissues.
The above conjectures share the assump-
tion that some innate function of the normal tumor 
suppressor genes leads to a tissue specific cancer 
response.   In contrast a different hypothesis is pro-
posed and tested here.  The tissue in which disease 
occurs is greatly influenced by the tissue specificity of 
the disease pathogen, of a specific chronic inflamma-
tory process or of a carcinogen.  The target tissue can 
contribute because it has receptors for the pathogen 
and provides conditions that allow disease.  An innate 
genomic deficit contributes because it exacerbates 
the susceptibility to disease wherever it attacks.  
This extrinsic challenge model of tissue speci-
ficity can be tested against a variety of independent 
and different lines of evidence.    Cancers of the liver, 
cervix and stomach are linked to known infections. 
Machida et al (2006), De Marzo et al (2007), Machado 
et al. (2009).  Damage from these infections and ac-
companying inflammation can be related to pathways 
mediated by BRCA1/2.  Acetaldehyde, a known car-
cinogen is causally linked to digestive tract and breast 
cancers, also has relationships to pathways containing 
BRCA1/2 and Fanconi anemia (FA) proteins.  Many 
independent lines of evidence support the idea that 
damage mediated by tissue specific pathogens, chronic 
inflammation, or a carcinogen gives tissue specificity 
to BRCA1/2 related cancers.  This model also accom-
modates data for several other tumor suppressors.
Materials and Methods
Test models for cancers with known 
relationships to pathogens or carcinogens.  
Cancers were chosen as initial test models because 
they all have widely accepted and well-known links 
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to pathogens or the carcinogen acetaldehyde.  Group 
1: liver cancer associated with viral hepatitis such as 
hepatitis B or C or liver and digestive tract cancer as-
sociated with the carcinogen acetaldehyde from alco-
hol metabolism; Groups 2-4:  vulvar, cervical, and head 
and neck cancers, all associated with human papilloma 
viruses (HPVs); and Group 5: stomach (gastric) cancer 
associated with helicobacter pylori. The literature was 
reviewed for associations between these agents and 
components within models for pathways containing 
BRCA1 and BRCA2.
Information sources.  PubMed and Google 
Scholar databases were systematically searched up 
through 2010, initially for original studies of non-
breast, non-ovarian cancers vs. any defect in a model 
for BRCA1/2 function (Fig. 1).  1300 articles published 
in the past 50 years were retrieved and copied to a 
database to facilitate computer searching and review.  
Many bibliographies were also reviewed for additional 
relevant references that may have been missed.  Ex-
plicit procedures were used to systematically identify, 
appraise, summarize and statistically aggregate rel-
evant studies.  Moher et al. (1999).
  Statistical analyses.   For meta-analyses, 
the random effects model was used (Dersimonian and 
Laird, 1986).  P values were derived from two-sided 
statistical tests. 
Results and Discussion
Evidence for interactions between in-
fections or a carcinogen linked to cancers and 
FA, BRCA1/2, and ATM.  A composite model (Fig. 
1) was derived incorporating numerous mechanistic 
studies that all picture BRCA1/2 functioning in a DNA 
repair pathway scheme together with FA proteins 
and ATM.  (D’andrea and Grompe, 2002), (Venkitara-
man, 2003), Bolderson et al. (2010), Pace et al. (2010), 
(Cohn and D’Andrea, 2008), (Whitby, 2010). 
This derived pathway gives a general outline 
for repair of DNA interstrand cross-links, stalled 
replication forks and double strand breaks.  Inherited 
defects in this repair outline were tested against risks 
for cancers with known links to pathogens, chronic in-
flammation and to acetaldehyde. Cancers of the liver, 
cervix, vulva, head-neck, and stomach were used as 
initial test tissue-specific cancers.  Acetaldehyde from 
alcohol metabolism was used as a test for exposure 
to a carcinogen that causes DNA cross-links. 
Multiple independent lines of evidence support 
the concept that pathogens, chronic inflammation or 
the carcinogen acetaldehyde greatly contribute to 
the tissue specificity of cancer in carriers of BRCA1, 
BRCA2, ATM and FA mutations.  These different types 
of evidence are numbered 1-10 and discussed below.  
In most cases each line of evidence is supported by 
multiple published observations. 
Ten lines of evidence supporting pathogens or 
a carcinogen determining tissue specificity of 
hereditary BRCA1/2 or other hereditary can-
cers
1. Chronic inflammation in cancer mod-
els and increased susceptibility in mutation 
carriers.     
As a sign of chronic inflammation, lymphocyte 
infiltration is present in five organ specific model can-
cers associated with specific infections (liver, cervix, 
vulva, head-neck, and stomach cancers).  People who 
inherit homozygous deficits in ATM or one of the FA 
genes within the pathway indicated in Fig. 1 have the 
diseases ataxia-telangiectasia (A-T) or Fanconi anemia 
(FA), respectively.  Both A-T and FA patients have ab-
normal responses to inflammation.  Ward et al (1994), 
(Ward and Rosin, 1993), Zanier et al (2004), Rosselli 
et al.(1994), Suhasini et al. (2009), Saito et al. (2003), 
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Sejas et al. (2007), Hadjur et al. (2001).  
A-T and FA patients also have strong risk fac-
tors for viral hepatitis (and liver cancer) because they 
require multiple transfusions.  FA-C deficiency has 
been shown to confer an unusually high susceptibility 
to viral transformation.  Liu et al. (1996).  Ashkenazi 
Jews (a group with a high incidence of BRCA1/2 and 
FA mutations) also seem unduly susceptible to HCV 
transmission and infectivity. Golan et al. (1996).   
2. Mechanisms of DNA damage due 
to infections / inflammation suggest repair is 
required but infections may inhibit repairs. 
Infection and inflammation of many tissues accompany 
upregulation of an inducible nitric oxide synthase 
that can produce excess nitric oxide for a prolonged 
period.  Nitric oxide derived reactive species cause 
DNA damage and have carcinogenic potential (Sawa 
and Ohshima, 2006).
Although other factors also contribute to can-
cer, three pathogens strongly associated with cancer 
are well-known to cause double strand breaks by in-
flammatory processes.  Specifically, HCV infection trig-
gers mitochondrial changes releasing reactive oxygen 
and nitrogen species.  This causes DNA double strand 
breaks.  Machida et al.(2006).    Similarly HPV-16 infec-
tion reduces reactive oxygen scavenging activity and 
makes cells unresponsive to H2O2 damage.   Lembo et 
al. (2006).  Infection with the bacteria h. pylori inhibits 
the ability to remove reactive oxygen intermediates 
by inhibiting scavenging enzymes.  Smoot et al. (2000).
3. Association of gene defects in the Fig. 
1 pathway with known infection / inflammation 
related cancers.  54% of FA patients who develop 
cancers caused by HPV (e.g. cervical or head-neck 
cancer) have evidence of HPV infection as condyloma.  
In comparison to non-FA cancer patients, odds of 
finding HPV infection in HNSCC in FA patients are 
8.85 [1.90 - 54.2].  Kutler et al. (2003a). 
BRCA2 mutation increases risks for stom-
ach cancer usually associated with h. pylori.   The 
standardized incidence ratio for stomach cancer in 
29 BRCA2 families was nearly 600 times normal.  
Jakubowska et al. (2002),  Jakubowska et al. (2003), 
Figer et al (2001).
4. Some types of infection / inflamma-
tion related damage requires BRCA1/2 medi-
ated pathways (Fig. 1).  Peroxynitrite derived from 
an inflammatory response produces DNA adducts 
that require BRCA1/2 and FA dependent homolo-
gous recombination for repair.   Peroxynitrite oxidizes 
guanine in DNA producing structures that then react 
with proteins such as histones or glycosylases to form 
large DNA-protein adducts or interstrand cross-links.   
The lesions are so bulky that BRCA1/2 dependent 
homologous recombination occurs in preference to 
nucleotide excision repair. Nakano et al. (2009).  Im-
paired homologous recombination (Fig. 1) would thus 
favor dangerous gene rearrangements if less specific 
repair methods then operate. Friedenson (2007), Pace 
et al (2010).   Another direct correlation is that the 
BRCA1 associated helicase FA-J (Fig. 1) is required 
to sense oxidative base damage in either strand of 
duplex DNA and unwinds the damaged DNA strand.  
Suhasini et al (2009).  Some damage from the alcohol 
related carcinogen acetaldehyde also depends on spe-
cific repairs in Fig 1.
5.  Associations between BRCA1/2, ATM, 
FA (Fig. 1) and viral cancers or viral proteins.   
A mutated BRCA1 gene was detected in 13/17 pre-
cancerous lesions of the cervix. Park et al (1999).  
Based on 404 cases of cervical cancer, the BRCA1 
variant genotype rs799917 TT was associated with 
decreased risk of cervical cancer. (OR= 0.62, CI=0.4-
0.95).   In 469 women with cervical cancer and 390 
women with HPV infection, a single nucleotide poly-
morphism in FA-A was associated with an increased 
risk for cervical cancer.  Wang et al. (2009).  FA-F 
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Figure 1
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Figure Legend
Figure 1.  Working test model for Derived DNA repair pathway containing BRCA1 and BRCA2 gene prod-
ucts.  The model was compiled based on (D’Andrea and Grompe, 2002),  Venkitaraman (2003),  Bolderson 
(2010), Pace et al, (2010), Cohn and D’Andrea, (2008).   For BRCA pathway components (colored red), risks 
have  been studied in mutation carriers for multiple cancers linked to known infections and inflammation.  
BRCA2 is the same as FA-D1 and this is indicated in the drawing.   The red components are involved in re-
pairing complex damage that occurs during inflammation or from a carcinogen such as acetaldehyde.  ATM is 
placed as initial signal transducer following detection of a double strand break.  Human exonuclease 1 (Exo 1) 
is required for double strand break repair by homologous recombination.  ATM is probably essential for rapid 
phosphorylation of Exo1.  In turn Exo1 phosphorylation is essential to recruit Rad51.  Phosphorylation of Exo1 
by ATM is dispensable for resecting double strand breaks but this likely interferes with homologous recombina-
tion due to defective loading of Rad51. Bolderson et al. (2010).  ATM also induces a cell cycle checkpoint and 
phosphorylates BRCA1 and FANCD2.  FA core complex proteins cause the ubiquitylation of FANCD2 which 
is then found in repair foci along with BRCA1 and BRCA2.  FANCD2 might antagonize Ku70 activity and divert 
double-strand break repair away from abortive NHEJ and toward homologous recombination. Pace et al (2010). 
One member of the FA core complex, FA-M is a DNA junction-specific helicase / translocase that targets and 
processes perturbed replication forks and intermediates of homologous recombination.  (Whitby, 2010), Gari 
et al. (2008).  Acetaldehyde from alcohol metabolism and inflammation also induce interstrand cross-links which 
characteristically require pathway components for repair.  BRCA1 is essential to form nuclear foci, believed to 
be sites of DNA repair.  BRCA2 aids the recruitment and loading of the RAD51 repair protein onto processed 
double strand breaks.  ATR, a kinase closely related to ATM is activated later when stalled replication forks form 
during replication of damaged DNA.  Bolderson et al. (2010).  The ATR signaling cascade re-enforces ATM-
induced cell cycle checkpoints.   
   Cancer risks for FA were measured before all the components were known and refer to FA genes 
as a group.  Not shown are numerous interactions involving BRCA1 or BRCA2 with other proteins, details of 
relationships to cell cycle checkpoints, and to estrogen signaling.   The drawing represents a working model that 
may actually represent the sum of simultaneous pathways activated in response to complex inflammation or 
acetaldehyde related DNA damage, requiring several different types of repair.  Inflammation also causes damage 
requiring other pathways for repair such as mismatch repair, base excision repair, etc.
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methylation was found in about 30% of 91 cervical 
cancers.  Woodman et al. (2007).
BARD1 (BRCA1 associated ring domain) 
protein binds to BRCA1, stabilizing both proteins 
and helping target BRCA1 to sites of DNA dam-
age.  BARD1 mutations contribute to some cases of 
sporadic and hereditary cancers of breast, ovary and 
uterus.  Zhou et al. (2009).   BARD1 forms a physi-
cal complex with the HPV protein E6 BARD1 and 
inactivates the expression of E6 in cervical cancer 
cells.  Yim et al. (2007).  BRCA1 is involved in complex 
interactions during a response to h. pylori mediated 
infections.  (Kim and Kim, 2009).
Infection with HPV activates the ATM-Chk2 
checkpoint pathway (Fig. 1).  This permits repair of 
damage by homologous recombination (Fig 1) and 
non-homologous end joining.  Not all damaged sites 
are repaired correctly leading to chromosomal trans-
locations, deletions and rearrangements.  Cellular 
defenses against integrated HPV re-replication are 
primarily coordinated by ATM.  ATM is visualized in 
the repair and recombination centers of cells infected 
with HPV.  Kadaja et al (2009).  An allelic imbalance at 
chromosome 11q (near or including ATM was found 
in 34 of 81 cervical cancers. Skomedal et al (1999).
Reduced activities of BRCA2, FA-J and ATM 
have been reported in HCV mediated hepatocellu-
lar carcinoma compared to normal uninfected cells.  
Ghaziani et al. (2006), Kondoh et al. (2001), Lai et al 
(2008).  HCV contains a helicase that interacts with 
host protein ATM, impairing repair of DNA double 
strand breaks and cross-links. 
6.  Relationship to a DNA interstrand 
cross-linking carcinogen.   Alcohol consumption 
increases risks for cancers of the upper aerodigestive 
tract, liver, colorectum, and female breast. Baan et al. 
(2007).  The sites for these cancers are influenced by 
acetaldehyde a known carcinogen produced during 
alcohol metabolism.    Acetaldehyde generates DNA 
–protein and interstrand cross-links.  The response to 
this damage results in a concentration-dependent in-
crease in FA-D2 mono-ubiquitylation, which is depen-
dent upon the FA core complex (Fig. 1).  The acetalde-
hyde DNA damage response is qualitatively similar to 
the cellular response to mitomycin C, the classic test 
for deficiencies in FA. Marietta et al (2009).  Alcohol 
also causes oxidative stress, endoplasmic reticulum 
stress, and inflammatory / immune responses.
7.  Increased risk for pancreatic and 
prostate cancers.  It is well known that BRCA1 
and/or BRCA2 mutation carriers have increased risks 
for pancreatic and prostate cancers. Kim et al. (2009),  
Agalliu et al (2009).  In normal individuals, chronic 
inflammation in the target organ predisposes to either 
cancer.  Patients with chronic alcoholic pancreatitis 
or with familial chronic pancreatitis have much higher 
incidence of pancreatic carcinoma.  Exposure to infec-
tious agents and carcinogens and hormonal imbal-
ances lead to prostate injury, to chronic inflammation 
and to high risk lesions. De Marzo et al (2007).  
8.  Other cancers with probable links 
to inflammation strongly correlate with bial-
lelic BRCA2 mutation.  In carriers of compound 
BRCA2 mutations, risks for other cancers associ-
ated with chronic infections and inflammation are 
very strongly linked to the presence of the mutation.  
Acute myeloid leukemias of the monocytic lineage can 
be induced reproducibly and with high incidence due 
to collaborative effects from severe chronic inflam-
mation and infection by specific retroviruses. Wolff et 
al. (1991).   In 6 children with biallelic BRCA2 muta-
tions, leukemia occurred in all 6 at a median age of 2.2 
years, with 4 of the 6 developing acute myeloid leuke-
mia.  Solid tumors with links to inflammation are also 
extraordinarily frequent.  Of 14 patients with biallelic 
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BRCA2 mutations, 5 died of early onset brain tumors, 
primarily medulloblastomas, and 3 developed Wilms 
tumors. Wagner et al. (2004). These are all cancers 
with known links to chronic infection/inflammation. In 
a formal review of biallelic BRCA2 mutation patients, 
Alter et al. (2007) similarly found dramatic risks for 
specific cancers with strong associations to inflamma-
tion.  Cumulative probability of leukemia (primarily 
AML) was 79% by age 10 years, that of a solid tumor 
was 83% by age 6.7 years, that of a brain tumor (pri-
marily medulloblastoma) was 85% by age 9 years, that 
of a Wilms tumor was 63% by age 6.7 years.  
9.  Hereditary colon cancer may involve 
different inherited genomic deficits but the 
site for cancer is still dictated by exposure to 
carcinogens.  Alcohol is causally linked to colon 
cancer in normal individuals. Baan et al (2007).  Alco-
hol metabolism produces acetaldehyde which causes 
damage requiring the Fig 1 pathway for repair.  In 
BRCA1/2 mutation carriers, colon cancer is difficult 
to detect because the average age of developing colon 
cancer (70 years) is the same as the life expectancy 
of a BRCA mutation carrier with mutation diagnosed 
at age 30.  Armstrong et al. (2004).  Very few patients 
in colon cancer clinics will therefore have BRCA1/2 
mutations.  Elevated risk for colon cancer has been 
reported in BRCA1 carriers.  Ford et al. (1994).  
Other studies conflict but  Thompson et al. (2002) 
found enough “digestive tract cancers” or unknown 
primary cancers to significantly change reported risks 
for colorectal cancers.  Colorectal cancer is a com-
mon cause for primary cancers with unknown origin.   
Based on a small study, a chromosomal marker near 
the BRCA1 gene may be a useful marker for iden-
tifying genetic instability in ulcerative colitis lesions 
leading to neoplastic development.  Matsumoto et al. 
(2003). 
These difficulties give added importance to 
colon cancer models that can test for the involve-
ment of Fig. 1.  In Atm deficient mice, feeding dextran 
sulfate induces colitis that clinically and experimentally 
resembles ulcerative colitis and its progression to 
colon cancer.  Markers of reactive oxygen and nitro-
gen species–mediated damage were greater in Atm 
deficient mice than in wild-type mice.  (Westbrook 
and Schiestl, 2010).  This again shows a carcinogen or 
mutagen (dextran sulfate) dictating the site for at least 
a cancer precursor in the presence of a general repair 
deficit.  
The colon comes into relatively prolonged 
contact with antigens, pathogens and mutagens in the 
diet.   The extent of inflammation and other dam-
age need not correlate with the cancer risk due to 
BRCA1/2 mutation alone.  Inflammation and reactive 
oxygen species cause a wide variety of damage to 
DNA including strand breaks, protein cross-linking 
and base modifications requiring multiple different 
repair pathways.  In addition to BRCA1/2 related 
pathways, various inflammation damage is repaired by 
mismatch repair, nucleotide excision repair, base exci-
sion repair, transcription coupled repair, etc.  More 
than 20 base lesions alone have been identified due 
to oxidative DNA damage.  The nature of the lesion 
is important in dictating this choice which need not 
involve BRCA1/2 pathways.  
 In one form of hereditary colon cancer, a 
glycosylase enzyme is missing that is needed for exci-
sion repair of 8-oxoguanine DNA, a by-product of 
inflammation in the colon.  Inherited defects in this 
enzyme (MUTYH) allow increases in 8-oxoguanine 
DNA. David et al (2007).   In studies of interactions 
with external factors, colon cancer risk for 8-oxogua-
nine glycosylase genotypes differed depending on 
dietary exposures such as the amount of meat in the 
diet.  Weiss et al. (2005).  Again, the carcinogen (and 
its route of ingestion, exposure,or metabolism) plays 
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a major role in determining the cancer site, with the 
hereditary deficit exacerbating risk by impairing the 
normal protective responses.  
MUTYH cancers are indistinguishable from 
the hereditary cancer condition familial adenomatous 
polyposis (FAP) associated with an inherited mutation 
in the APC gene.    The intestine develops hundreds 
to thousands of polyps and some progress to invasive 
cancers. FAP patients have elevated risk for infec-
tion and inflammation related cancers, reminiscent of 
patients with inherited mutations in BRCA1/2, ATM 
and FA. The risk of hepatoblastoma in FAP is 750 to 
7500 times higher than in the general population. The 
majority of hepatoblastomas occur before age three 
years.  Nearly half of FAP patients get gastric cancer 
and are at elevated risk for medulloblastoma.  Lifetime 
risk for pancreatic adenocarcinoma is about 2%.  (Burt 
and Jasperson, 2008)  These are all cancers with strong 
links to known chronic infections and /or  inflamma-
tion. 
How disruption of APC function contributes 
to cancer is poorly understood.  Ceol et al. 2007.  
Involvement of APC in the surveillance mechanism of 
accurate mitosis has been proposed. Abal et al. (2007).  
Whatever the mechanism of hereditary APC related 
cancers, chronic inflammation in the colon exacer-
bates cancer risks.  Anti-inflammatory drugs (NSAIDs) 
reduce the number and the size of adenomatous 
polyps.
Heterozygous non-polyposis colon cancer 
(HNPCC) is associated with an inherited deficit in 
mismatch repair.  In addition to elevated colon can-
cer risk, lifetime risk for pancreatic cancer (which 
has strong links to inflammation) is 8.6 times greater 
than in the general population.  Kastrinos et al. (2009). 
Elevated risks for ovarian, stomach and urinary tract 
cancer have also been reported.  Kastrinos et al. 
(2008).   A clinical trial studied effects of the anti-
inflammatory aspirin.  Cancer victims in the aspirin 
group were outnumbered 2 to 1 with a clear effect 
for duration of treatment. Burn et al. (2009). 
10.  Summarizing relative risks from 
high quality epidemiologic studies of mutation 
carriers shows that three chronic inflamma-
tory infections greatly increase cancer risks in 
FA,BRCA1/2 and ATM mutation carriers.  Table 
1 shows RR data from FA, BRCA1/2 and ATM muta-
tion carriers for five organ specific cancers with well-
known associations with chronic infection/ inflamma-
tion – cancer of the liver, cervix, vulva, head and neck 
area, and stomach.  For these cancers, the pathogen 
is an important factor in determining which cancer 
occurs.  
For homozygotes each of three available stud-
ies gives very large RR values for cancers of the liver, 
cervix, vulva and head and neck area.  Summary RR 
values are hundreds of times above control groups 
(Table 1, top row), with onset accelerated into early 
ages. (Alter, 2003)  For heterozygotes, results sum-
marized in Table 1 show that a deleterious mutation in 
BRCA1, BRCA2 or ATM genes greatly increases risks 
for cancers known to be linked to chronic infection.   
There are strong precedents for the idea that 
the same process can be inactivated at multiple points. 
Cancer genome sequences show that more than one 
mutation within the same pathway is unusual (Vo-
gelstein and Kinzler, 2004).  Other processes such as 
mismatch repair that depend on multiple genes can be 
inactivated by inactivating any of several genes encod-
ing proteins within the pathway.   The model pathway 
in Fig. 1 suggests that ATM, BRCA1, BRCA2 and FA 
genes encode proteins needed to repair DNA damage 
to specific organs caused by pathogens, inflammation 
or carcinogens.  Models for BRCA repair functions 
11
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that differ from Fig. 1 are still consistent with a role in 
repairing DNA damage related to pathogens, inflam-
mation, or carcinogens.  Cohn and D’Andrea (2008) 
Knipscheer et al. (2009).  (Whitby, 2010), Gari et al 
(2008).
Hereditary Cancers are also targeted to breast 
and ovary by inflammatory processes.  
Although investigated by many groups, no 
pathogens, sources of chronic inflammation or car-
cinogens have been conclusively linked to breast and 
ovarian cancer.   However there is evidence that these 
mechanisms operate in hereditary breast and ovarian 
cancer.  The distal fimbrial end of the fallopian tube is 
an important site for cancer genesis in BRCA1/2 mu-
tation carriers. Hirst et al. (2009), Crum et al. (2007).  
Callahan et al (2007), Cass et al. (2005), Demopoulos 
et al. (2001), Lee et al. (2007).  
Tubal ligation protects against ovarian 
cancer. 30 publications show an inverse association 
between ovarian cancer risk and tubal ligation based 
on data from hundreds of thousands of women.  In 
mutation carriers, pooled OR = 0.69 (95% CI = 0.55-
0.85) for risk of ovarian cancer after tubal ligation.  
Tubal ligation substantially reduces ovarian cancer risk 
for BRCA1 carriers.  McGuire et al. (2004), McGlaugh-
lin et al. (2007), Narod et al. (2001), Rutter et al. 
(2003), Antoniou et al (2009).  
Tubal ligation commonly removes sections of 
tubes between the uterus and fimbria, presumably 
preventing infection/inflammation from reaching the 
distal ends.    This suggests pathogens, infection/inflam-
mation, or carcinogens must travel through the tube 
to cause ovarian cancer. 
Talc use has been associated with ovar-
ian cancer.  It is well known that talc causes inflam-
mation in the pleural cavity.  In the past some talc 
contained asbestos fibers.  Talc reaches the upper 
abdominal cavity and is detected in surgically removed 
ovaries.  RR for ovarian cancer as high as 4.8 (2.1-11) 
have been reported. Gates et al. (2008). However this 
risk in mutation carriers has not been studied.
Inhibiting ovulation reduces risk for 
ovarian cancers.  Ovulation itself may cause inflam-
mation in both the ovary and the fimbria.    At the 
site of ovum release, leukocyte invasion, release of 
nitric oxide and inflammatory cytokines, vasodilation, 
DNA repair, and tissue remodeling (resembling wound 
healing) all occur. Fleming et al (2006). Any use of oral 
contraceptives (OC) decreases ovarian cancer risk in 
BRCA1 mutation carriers.  HR =  0.52; ( 0.37-0.73; p 
= 0.0002)  Increasing duration of OC use was as-
sociated with a reduced ovarian cancer risk in both 
mutation carriers and in normal women.   Antoniou 
et al (2009), Siskind et al. (2000).  Oral contaceptives 
however may fuel latent or undiscovered cancers.  
Tumor infiltrating lymphocytes in hered-
itary ovarian and breast cancers.  Intraepithelial 
CD8+ T-cells correlated with the presence of mutation 
or loss of expression of BRCA1 through promoter 
methylation. Clarke et al. (2009).  Macrophages may 
also be found in ovarian tumors. Fleming et al. (2006)
In normal women, transitions from normal 
breast to benign proliferative breast disease to duc-
tal carcinoma in situ to infiltrating ductal carcinomas 
were associated with significantly increased mean 
densities of inflammatory cell infiltrates.  Large in-
creases in infiltrates occur in the precursor form be-
nign proliferative breast disease compared to stroma 
(Hussein and Hassan, 2006).  Breast inflammation as 
lobulitis was found in 21/41 prophylactic mastectomy 
specimens from high risk women vs. 8/82 controls. 
Hermsen et al (2005).  BRCA1/2 mutation carriers 
have a denser lymphoid infiltrate in breast cancers 
compared to matched, sporadic control group. Adem 
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et al (2003).  Cancers associated with BRCA1 muta-
tions had more lymphocytic infiltration than sporadic 
, control cancers.  Lakhani et al (1998), Adem et al 
(2003), (Lakhani, 1999) and a higher expression of 
lymphocyte specific genes on microarray analysis. van’t 
Veer et al (2002).  Medullary cancer is more frequent 
in BRCA1/2 mutation carriers and is also closely as-
sociated with a dense lymphocyte infiltrate. Kuroda et 
al. (2005).   
Infection associated gene signature sug-
gests a deregulated immune or inflammatory 
response to some pathogen.   Genes important 
for immunity to infection and for removal of abnormal 
cells are over expressed in normal parous women but 
are not over expressed in BRCA1 carriers.  Buckley 
et al (2007). BRCA1 expression is essential to up-reg-
ulate a group of IFN-gamma controlled genes includ-
ing an anti-viral protein (8-fold) and an antigen pre-
sentation protein (2-fold). Buckley et al (2007). 40% of 
96 breast cancer samples had a strong signature for 
an interferon induced pathway. Einav et al. (2005).  
 Candidate sources for breast carcino-
genesis and for infection / inflammation.  Alco-
hol consumption has been causally linked to breast 
cancer.  Baan et al. (2007).  Candidate sources for 
pathogens or infection / inflammation underlying 
breast cancer include human endogenous retroviruses 
(HERV).  HERV-like sequences are integrated within 
the human genome.  Expression of these sequences 
can cause inflammatory responses.  Strong antibody 
and T-cell responses to HERV antigens have been 
found in women with early onset breast cancer and 
other breast cancer patients.  HERV was reactivated in 
88% of breast cancer samples including young women 
at greater risk for BRCA1/2 mutations but not in con-
trols. Wang-Johanning et al. (2008).  BRCA1/2 status 
was not determined but most breast cancers oc-
curred in younger age patients (ages  <=55  and < 50). 
Wang-Johanning et al. (2008).  RNA expression from 
retrovirus was  found in high titer in circulating blood 
from 20 breast cancer patients Contreras-Galindo et 
al (2008).  
Viruses including EBV, a human equivalent of 
mouse mammary tumor virus (MMTV), and HPV have 
been detected in benign breast tissues and breast 
tumors.  All are candidate pathogens or sources of in-
fection and inflammation that might give rise to breast 
cancer.  De Villiers et al. (2004) demonstrated the 
occurrence of HPV in high percentages of nipple and 
areolar tissues in patients with breast carcinoma but 
another study disagreed.  De Cremoux et al. (2008).
NSAIDs.  Anti-inflammatory NSAIDs reduce 
ovarian cancer risk in nulliparous women when other 
effect modifiers are corrected.  Wernli et al (2008) 
found OR=0.47(0.27-0.82) for nulliparous women and 
OR=0.58 (0.42-0.80) for women who had never used 
oral contraceptives.  Five meta-analyses including up 
to 91 studies, involving millions of subjects comparing 
NSAID users to non-users find that NSAIDs protect 
against breast cancer. Takkouche et al. (2008).  In a 
2010 study, Brasky et al. found that recent aspirin 
use was inversely associated with breast cancer risk 
(adjusted OR 0.80, 95% CI: 0.68-0.94); the greatest re-
duction in risk occurred among those who took >/=2 
aspirin pills/day (OR 0.74, 95% CI: 0.61-0. 90). 
NSAID results that specifically address breast 
cancer risk in BRCA1 or BRCA2 mutation carriers 
are needed, but there are results from women with 
a family history of breast cancer.  Harris et al (2003) 
studied NSAID use in 3546 women with a family 
history of breast cancer as part of the very large 
Women’s Health Initiative (WHI) study.  Stratification 
according to family history is more likely to repre-
sent mutation carriers than stratification according to 
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other variables (body mass index, hormone replace-
ment therapy, parity under age 30, or strenuous exer-
cise).   After age adjustment or multivariate analyses, 
women with a family history of breast cancer who 
used NSAIDs had the greatest apparent reduction in 
RR.  However confidence intervals overlapped other 
strata.  Harris et al. (2003).
Conclusion  
Mutations in BRCA1/2 genes and other he-
reditary mutations increase cancer risks from chronic 
infection, inflammation, pathogens and at least one 
carcinogen which contribute to selecting the site 
where hereditary cancer develops.   This information 
may be useful to prevent or delay cancers in mutation 
carriers.  
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Table 1  Cancer risks linked to chronic inflammatory infections at specific organ targets in cohorts with mutations 
in FA, BRCA1, BRCA2 and ATM
Genetic inheri-
tance
RR Liver Cancer 
[95% Confidence 
Interval]
RR Cervix Cancer 
[95% Confidence 
Interval]
RR Stomach Cancer 
[95% Confidence 
Interval]
RR Head Neck Cancer 
[95% Confidence 
Interval]
References
FA gene homozy-
gotes
478.6 [255.9 -  
895.2], I2=0
193.5 [74.81 -  
500.7], I2= 44%
202.2 [138.0 -  296.4] 
I2=0
Alter (2003,) Kutler et 
al. (2003b), Rosenberg 
et al (2003)
BRCA1 
heterozygotes
4.06 [1.77 -  9.34] 3.84 [2.33 - 6.33]
1.56 [0.91 - 2.68] 
Peritoneal, intestinal 
tract” abdomen not 
otherwise specified” 
cancers were also 
found and reported 
as “other” cancers.
0.15 [0.06 - 0.40] as 
“buccal cavity and phar-
ynx” cancers.  RR=7.40 
[5.14-10.66] for “other” 
cancers including 
paranasal sinus cancers 
often originating in the 
oropharynx 
Thompson et al. (2002)
BRCA2 
heterozygotes or 
presumptive 
4.18 [1.56 – 11.23], 
I2=0
2.26 [0.71 -  7.19], 
I2= 42%
2.76 [1.77 -  4.29], 
I2=0 2.26 [1.22 - 4.17], I
2=0
Hemminki et al. (2005), 
Johannsson et al. (1999), 
Breast Cancer Linkage 
Consortium (1999)
ATM heterozy-
gotes
3.82 [2.23 -  6.55], 
I2=0
3.06 [1.83 -  5.11], 
Moment based 
between study 
variance = 0
3.66 [1.29 – 5.78], 
I2= 1.6%
Geoffrey-Perez et 
al. (2001) Olsen et 
al. (2005) Swift et al. 
(1976)
RR Data pooled 
from heterozy-
gous carriers 
of mutation in 
BRCA1, BRCA2 
or ATM
3.87 [2.58-5.81], 
I2=0
3.14 [2.27 - 4.35], 
I2= 1.1%
2.38 [1.64 -  
3.45],I2= 42%
2.26 [1.22 -  4.71] 
I2=0% for subgroup 
(buccal cavity, pharynx 
or oral cavity)
Thompson et al (2002) 
Hemminki et al. (2005), 
Johannsson et al 
(1999), Breast Cancer 
Linkage Consortium 
(1999 Geoffrey-Perez 
et al (2001) Olsen 
et al (2005) Swift et 
al (1976)), Evans et al 
(2001)
Legend to Table 1.  Risks for cancers of the liver, cervix, stomach and head and neck area are shown separately in 
rows 2-4 for heterozygous mutations in BRCA1, BRCA2 and ATM.  In the bottom row these risks are calculated by 
pooling RR data from BRCA1, BRCA2, probable BRCA1/2 (untyped), and ATM  heterozygous carriers. This pooled data 
includes 24, 272 heterozygotes as19,765 BRCA1/2 heterozygotes or potential heterozygotes and 4507 ATM heterozy-
gotes or potential heterozygotes  The effects of different variables on the statistical results and the robustness of the 
results were measured by performing meta-analyses using many different combinations of studies and study arms.  
Heterogeneity testing (as I2 or between study variance) evaluated whether the effect size in different subgroups (defined 
biologically or medically) varied significantly from the main effect.   An I2 value >50% generally indicates significant het-
erogeneity. Higgins et al. (2003).  For cervical cancer, a possible source of inconsistency may be differences in Pap testing.  
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Stomach cancer may be underestimated in BRCA1 carriers significant numbers of “abdomen not otherwise specified” as 
well as peritoneal, and intestinal tract cancers were reported Thompson et al (2002).  Moreover, stomach cancer typically 
occurs late in life and is subject to competing risks.  Subgroup analysis suggested RR values and inconsistency in head and 
neck cancer studies (87.1%) may partly depend on differences in defining head and neck cancers.  Three studies reported 
HNSCC as cancer of the buccal cavity and/or pharynx or oral cavity.  A subgroup of these three studies gives a summary 
RR=2.26 [1.22- 4.17] with 0% inconsistency.  However, HPV is most clearly associated with oropharyngeal cancer (63% in 
the US), arising predominantly from the lingual and palatine tonsils.  D’Souza et al. (2007).  The one study that specifically 
reported oropharyngeal cancer also found the highest RR. Evans et al. (2001).  
Details of these calculations have been reported elsewhere (Friedenson, accepted for publication, 2010). Briefly, cohorts in 
the table had a documented mutation in the family and/or numerous breast or other cancers at age <60.  Inherited defects 
were in FA proteins, BRCA1, BRCA2 or the upstream activator ATM.   Studies of groups having a known probability of car-
rying a mutation <25% (3 studies) were excluded.   Other exclusion criteria were > 20%  of subjects lost due to mortality, 
illness, refusal to participate, missing information, lost branches of family trees, dropouts, etc.  or some other preselection 
such as ignoring family branches likely to have cancer (7 studies).  Any of these criteria would potentially weight results for 
cancer survivors or people who never get cancer.  (Friedenson 2009).   No assumptions were made about the risk for a 
cancer at any individual site unless the study reported incidence at the site.   
In order to qualify for inclusion, a study had to meet the following a priori criteria of quality.   The study had to (1) have 
sufficient follow-up (1-10 years) (2) include incidence data from >100 individuals for cancers beyond breast and ovarian 
cancer, (3) have a probability of mutation >=25%, assuming a positive family history (4) provide relative risks for cancers be-
yond breast and ovarian, with confidence intervals (CIs) or sufficient data to allow calculation of RRs and CIs.  A standard 
protocol was followed to extract data from each included study.   
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
References 
Abal M, Obrador-Hevia A, Janssen KP, Casadome L, Me-
nendez M, Carpentier S, Barillot E, Wagner M, Ansorge W, 
Moeslein G, Fsihi H, Bezrookove V, Reventos J, Louvard 
D, Capella G, Robine S. (2007).  APC inactivation associ-
ates with abnormal mitosis completion and concomi-
tant BUB1B/MAD2L1 up-regulation. Gastroenterology. 
132(7):2448-58. 
Adem C, Reynolds C, Soderberg CL, Slezak JM, McDon-
nell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann 
LC, Jenkins RB (2003). Pathologic characteristics of breast 
parenchyma in patients with hereditary breast carcinoma, 
including BRCA1 and BRCA2 mutation carriers.  Cancer 
97: 1-11. 
Agalliu I, Gern R, Leanza S, Burk RD. (2009).  Associations 
of high-grade prostate cancer with BRCA1 and BRCA2 
founder mutations. Clin Cancer Res. 15(3):1112-20.
Alter B (2003). Cancer in Fanconi Anemia, 1927–2001.  
Blood  97: 425-440.
Alter B, Rosenberg P, Brody L. (2007).  Clinical and molecu-
lar features associated with biallelic mutations in FANCD1/
BRCA2 J Med Genet. 44:1–9. 
Antoniou A, Rookus M, Andrieu N, Brohet R, Chang-Claude 
J. (2009). Reproductive and hormonal factors, and ovar-
ian cancer risk for BRCA1 and BRCA2 mutation carriers: 
results from the International BRCA1/2 Carrier Cohort 
Study. Cancer Epidemiol. Biomarkers Prev. 18: 601-10. 
Aretz S, Stienen D, Friedrichs N, Stemmler S, Uhlhaas S, 
Rahner N, Propping P, Friedl W. Somatic APC mosaicism: 
a frequent cause of familial adenomatous polyposis (FAP). 
(2007).  Hum Mutat. 28: 985–92.
Armstrong K, Schwartz S, Randal T, Rubin S, Weber B. 
(2004) Hormone Replacement Therapy and Life Expec-
tancy After Prophylactic Oophorectomy in Women With 
BRCA1/2 Mutations: A Decision Analysis.   J. Clin Oncol. 
22(6):1045-1054
Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bou-
vard V, Altieri A, Cogliano V; WHO International Agency for 
Research on Cancer Monograph Working Group. Carci-
nogenicity of alcoholic beverages (2007).  Lancet Oncol. 
8(4):292-3.
Baldridge M, King K, Boles N, Weksberg D, Goodell M 
(2010).  Quiescent haematopoietic stem cells are activated 
by IFN-g  in response to chronic infection.  Nature 465: 
793-797
Bolderson E, Tomimatsu N, Richard D, Boucher D, Kumar 
R, Pandita T, Burma S, Khanna K (2010).  Phosphorylation 
of Exo1 modulates homologous recombination repair of 
DNA double strand breaks.  Nucl Acids Res 38: 1821-1831.
Brasky T, Bonner M, Moysich K, Ambrosone C, Nie J, Tao 
M, Edge S, Kallakury B, Marian C, Trevisan M, Shields P, 
Freudenheim J. (2010) Non-steroidal anti-inflammatory 
drug (NSAID) use and breast cancer risk in the Western 
New York Exposures and Breast Cancer (WEB) Study. 
Cancer Causes Control. 2010 May 25. 
Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, 
Harkin DP, Mullan PB  (2007). BRCA1 regulates IFN-γ sig-
naling through a mechanism involving type 1 IFNs.  Molec 
Cancer Res. 5: 261-70.
Burn J, Mathers JC, Gerdes AM, et al. (2009) Cancer oc-
currence during follow-up of the CAPP2 study—aspirin 
use for up to 4 years significantly reduces Lynch syndrome 
cancers for up to10 years. Available from: URL http://www.
capp2.com/newsZone/readnews.php?NewsID=45
Burt RW, Jasperson KW. (2008) In: Pagon RA, Bird TC, 
Dolan CR, Stephens K, editors. GeneReviews [Internet]. 
Seattle (WA): University of Washington, Seattle; 1993-.1998 
Dec 18 [updated 2008 Jul 24].  APC-Associated Polyposis 
Conditions.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, 
Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG 
(2007).  Primary Fallopian tube malignancies in BRCA-
positive women undergoing surgery for ovarian cancer risk 
reduction.  J. Clin. Oncol.. 25: 3985-90.  
Cass I, Holschneide C, Datta N, Barbuto D, Walts A,  Karlan 
B. (2005). BRCA-mutation-associated fallopian tube carci-
noma.  A distinct clinical phenotype.  Obstet. Gynecol. 106: 
1327-1334.
Ceol CJ, Pellman D, Zon LI. (2007).  APC and colon cancer: 
two hits for one. Nat Med. 13(11):1286-7.
Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, 
Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, 
Huntsman DG, Coukos G, Gilks CB (2009) Intraepithelial 
T cells and prognosis in ovarian carcinoma:  novel associa-
tions with stage, tumor type, and BRCA1 loss.  Modern 
Pathol. 22: 393-402.
Cohn M and D’Andrea A (2008). Chromatin Recruitment 
of DNA Repair Proteins: Lessons from the Fanconi Anemia 
and Double-Strand Break Repair Pathways.  Molec. Cell 32: 
306-312.
Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Fer-
lenghi I, Bagnoli F, Giusti F, Dosik MH, Hayes DF, Gitlin SD, 
Markovitz DM. (2008).  Human Endogenous Retrovirus K 
(HML-2) Elements in the plasma of people with lymphoma 
and breast Cancer.  J. Virol.  82: 9329–9336. 
Crum C, Drapkin R, Kindelberger D, Medeiros F, Miron 
A, Lee Y (2007).  Lessons from BRCA: the tubal fimbria 
emerges as an origin for pelvic serous cancer.  Clin. Med. & 
Res. 5: 35-44,    
D’Andrea A, Grompe M (2003).  The Fanconi anaemia/
BRCA pathway. Nature Rev. Cancer 3: 23-34.
David SS, O’Shea VL, Kundu S. (2007) Base-excision repair 
of oxidative DNA damage. Nature. 447(7147):941-50.
de Cremoux P, Thioux M, Lebigot I, Sigal-Zafrani B, Salmon 
R, Sastre-Garau X; Institut Curie Breast Group (2008).  No 
evidence of human papillomavirus DNA sequences in inva-
sive breast carcinoma. Breast Cancer Res Treat. 109(1):55-
8.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, 
Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007).  Inflam-
mation in prostate carcinogenesis.  Nature Rev. Cancer 7: 
256-269. 
Demopoulos R, Aronov R, Mesia A. (2001). Clues to the 
Pathogenesis of Fallopian Tube Carcinoma:  A Morphologi-
cal and Immunohistochemical Case Control Study,  Inter-
nat. Journal of Gynecol. Pathol. 20: 128–132. 
DerSimonian R, Laird N (1986).  Meta-Analysis in clinical 
trials.  Controlled Clin. Trials 7: 177-188. 
de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE 
(2005).  Presence of papillomavirus sequences in condy-
lomatous lesions of the mamillae and in invasive carcinoma 
of the breast. Breast Cancer Res.7(1):R1-11. 
Dizin E, Irminger-Finger I (2010). Negative feedback loop 
of BRCA1-BARD1 ubiquitin ligase on estrogen receptor 
alpha stability and activity antagonized by cancer-associated 
isoform of BARD1. Int J Biochem Cell Biol. 42(5):693-700. 
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, 
Koch WM, Westra WH, Gillison ML. (2007).  Case-control 
study of human papillomavirus and oropharyngeal cancer. 
N Engl J Med. 356(19):1944-56.
Einav U, Tabach Y, Getz G, Yitzhaky A, Ozbek U, Amariglio 
N, Izraeli S, Rechavi G, Domany E (2005).  Gene expression 
analysis reveals a strong signature of an interferon induced 
pathway in childhood lymphoblastic leukemia as well as in 
breast and ovarian cancer.  Oncogene. 24: 6367-6375,.
Evans H, Lewis C, Robinson D, Bell C, Møller H, Hodgson 
S. (2001). Cancer risks in women with 2 breast or ovarian 
cancers:  clues to genetic susceptibility.  Internat. J. Cancer. 
94: 758-9. 
18
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
Fan, S., Ma, Y.X., Wang, C., Yuan, R.Q., Meng, Q., Wang, J.A., 
Erdos, M.,Goldberg, I.D., Webb, P., Kushner, P.J., et al. (2001). 
Role of direct interactionin BRCA1 inhibition of estrogen 
receptor activity. Oncogene 20: 77–87.
Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A, Friedman 
F (2001).  The rate of the 6174delT founder Jewish muta-
tion in BRCA2 in patients with non-colonic gastrointestinal 
tract tumours in Israel.  Brit. J. Cancer 84: 478-81. 
Fleming J, Beaugie C, Haviv I, Chenevix-Trench G,  Tan O 
(2006).  Incessant ovulation and epithelial ovarian carcino-
genesis:  revisiting old hypotheses.  Mol. Cell Endocrinol. 
247: 4-21.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar 
DE.(1994). Risks of cancer in BRCA1-mutation carriers.  
Breast Cancer Linkage Consortium. Lancet. 343(8899):692-
5.
Friedenson B (2007). The BRCA1/2 pathway prevents 
hematologic cancers in addition to breast and ovarian can-
cers.  BMC Cancer. 7,  pp. 152-ff.  
Friedenson B (2009). DEWEY DEFEATS TRUMAN and 
cancer statistics. J. Natl Cancer Inst. 101, no.16, 1157. 
Gardner K, Liu E.(2001).  BRCA1 function in T lympho-
cytes: a cellular specificity of a different kind. Breast Cancer 
Res 3:11-13.
Gari K, Décaillet C,  Stasiak A,  Stasiak A, Constantinou A 
(2008). The Fanconi Anemia Protein FANCM Can Promote 
Branch Migration of Holliday Junctions and Replication 
Forks. Molec. Cell, 29: 141-148
Gates MA, Tworoger SS, Terry KL, Titus-Ernstoff L, Rosner 
B, De Vivo I, Cramer DW, Hankinson SE (2008). Talc use, 
variants of the GSTM1, GSTT1, and NAT2 genes, and risk 
of epithelial ovarian cancer.  Cancer Epidemiol. Biomarkers 
Prev. 17: 2436-44. 
Geoffroy-Perez B, Janin N, Ossian K, Laugé A, Croquette 
MF, Griscelli C, Debré M, Bressac-de-Paillerets B, Aurias 
A, Stoppa-Lyonnet D, Andrieu N ( 2001).  Cancer risk in 
heterozygotes for ataxia-telangiectasia.  Internat. J. Cancer 
93: 288-293.
Ghaziani T, Shan Y, Lambrecht R, Donohue S, Pietschmann 
T, Bartenschlager R, Bonkovsky H. (2006).  HCV proteins 
increase expression of heme oxygenase-1 (HO-1) and 
decrease expression of Bach1 in human hepatoma cells.  J. 
Hepatology 45: 5-12. 
Golan E, Korzets Z, Cristal-Lilov A, Ben-Tovim T, Bern-
heim J. (1996). Increased prevalence of HCV antibodies in 
dialyzed Ashkenazi Jews--a possible ethnic predisposition.  
Nephrology Dialysis Transplantion 11: 684-6. 
Gompel, A., Somai, S., Chaouat, M., Kazem, A., Kloosterboer, 
H.J.,Beusman, I., Forgez, P., Mimoun, M., Rostene, W. (2000). 
Hormonal regulation of apoptosis in breast cells and tis-
sues. Steroids 65: 593–598.
Hadjur S, Ung K, Wadsworth L, Dimmick J, Rajcan-Sep-
arovic E, Scott RW, Buchwald M, Jirik FR (2001). Defective 
hematopoiesis and hepatic steatosis in mice with combined 
deficiencies of the genes encoding Fancc and Cu/Zn super-
oxide dismutase.  Blood  98:1003-11.
Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, 
Anderson G, Loar A, Rodabough R, White E, McTiernan A; 
Women’s Health Initiative (2003).  Breast cancer and non-
steroidal anti-inflammatory drugs: prospective results from 
the Women’s Health Initiative. Cancer Res. 63(18):6096-
101.
Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, 
Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer 
EV, Chia KS, Pompe-Kirn V, Martos C, Jonasson JG, Li X, 
Brennan P (2005)  Second primary malignancies in patients 
with male breast cancer.  Brit. J. Cancer 92 : 1288-92.
Hermsen B, von Mensdorff-Pouilly S, Fabry H, Winters H, 
Kenemans P, Verheijen R, van Diest P (2005). Lobulitis is a 
frequent finding in prophylactically removed breast tissue 
from women at hereditary high risk of breast cancer.   J. 
19
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
Pathol. 206: 220-3.
Higgins J, Thompson S, Deeks J, Altman D. (2003). Measur-
ing inconsistency in meta-analyses.  Brit. Medical  Journal 
327:  557-60.
Hirst JE, Gard GB, McIllroy K, Nevell D, Field M (2009). 
High rates of occult fallopian tube cancer diagnosed at pro-
phylactic bilateral salpingo-oophorectomy.  Int J Gynecol 
Cancer19(5): 826-9.  
Hussein M, Hassan H (2006). Analysis of the mononuclear 
inflammatory cell infiltrate in the normal breast, benign 
proliferative breast disease, in  situ and infiltrating ductal 
breast carcinomas: preliminary observations.  J. Clin. Pathol. 
59: 972–977. 
Jakubowska A, Nej K, Huzarski T, Scott R, Lubiński J (2002).  
BRCA2 gene mutations in families with aggregations of 
breast and stomach cancers.  Brit. J. Cancer 87: 888-91.
Jakubowska A, ScottR, Menkiszak J, et al. (2003).  A high 
frequency of BRCA2 gene mutations in Polish families with 
ovarian and stomach cancer.  European J. Human Genet. 11: 
955-8.
Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, 
Olsson H (1999)  Incidence of malignant tumours in rela-
tives of BRCA1 and BRCA2 germline mutation carriers.  
European J. Cancer. 35,  pp. 1248-1257. 
Joosse S,  van Beers E, Tielen I, Hugo Horlings H, Peterse 
J, Hoogerbrugge N, Ligtenberg M, Wessels L, Axwijk P, 
Verhoef S, Hogervorst F, Nederlof P (2009). Prediction of 
BRCA1-association in hereditary non-BRCA1/2 breast 
carcinomas with array-CGH.  Breast Cancer Res Treat  
116:479–489
Jönsson G, Naylor TL, Vallon-Christersson J, Staaf J, Huang 
J, Ward MR, Greshock JD, Luts L, Olsson H, Rahman N, 
Stratton M, Ringnér M, Borg A, Weber BL. (2005). Distinct 
genomic profiles in hereditary breast tumors identified by 
array-based comparative genomic hybridization. Cancer 
Res.65(17):7612-21.
Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M  (2009).  
Mechanism of genomic instability in cells infected with 
the high-risk human papillomaviruses. PLoS Pathog. 
5(4):e1000397.
Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Ray-
mond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S.  
(2009).  Risk of pancreatic cancer in families with Lynch 
syndrome.  JAMA 302(16):1790-5.  
Kastrinos F, Stoffel EM, Balmaña J, Steyerberg EW, Mercado 
R, Syngal S. Phenotype comparison of MLH1 and MSH2 
mutation carriers in a cohort of 1,914 individuals under-
going clinical genetic testing in the United States (2008).  
Cancer Epidemiol Biomarkers Prev. 7(8):2044-51.
Kim DH, Crawford B, Ziegler J, Beattie MS (2009).  Preva-
lence and characteristics of pancreatic cancer in families 
with BRCA1 and BRCA2 mutations. Fam Cancer. 8(2):153-
8.
Kim KK, Kim HB. (2009). Protein interaction network 
related to Helicobacter pylori infection response. World J 
Gastroenterol. 15(36):4518-28.
King M-C, Marks J, Mandell, J (2003).   Breast and ovarian 
cancer risks due to inherited mutations in BRCA1 and 
BRCA2. Science 302: 643 – 646.
King M-C, Wieand S,  Hale K, et al. (2001). National Surgical 
Adjuvant Breast and Bowel Project, Tamoxifen and breast 
cancer incidence among women with inherited mutations 
in BRCA1 and BRCA2: National Surgical Adjuvant Breast 
and Bowel Project (NSABP-P1) Breast Cancer Prevention 
Trial.  JAMA 286: 2251-6.
Knipscheer P, Räschle M, Smogorzewska A, Enoiu M, Ho 
TV, Schärer OD, Elledge SJ, Walter JC (2009). The Fanconi 
anemia pathway promotes replication-dependent DNA 
interstrand cross-link repair. Science 326(5960):1698-701
Kondoh N, Wakatsuki T,  Hada A, Shuda M, Tanaka K, Arai M, 
Yamamoto M (2001).  Genetic and epigenetic events in hu-
20
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
man hepatocarcinogenesis.  Internat. J. Oncol. 18: 1271-8.
Kohno H, Takahashi M, Yasui Y, Suzuki R, Miyamoto S, 
Kamanaka Y, Naka M, Maruyama T, Wakabayashi K, Tanaka 
T. (2007) A specific inducible nitric oxide synthase inhibi-
tor, ONO-1714 attenuates inflammation-related large 
bowel carcinogenesis in male Apc(Min/+) mice. Int J Cancer. 
121(3):506-13.
Kuroda H, Tamaru J-I, Sakamoto G,. Ohnisi K, Itoyama S 
(2005).  Immunophenotype of lymphocytic infiltration in 
medullary carcinoma of the breast. Virchows Archives  vol. 
446: 10-14.
Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish 
SD, Huvos AG, Goberdhan A, Shah JP, Singh B (2003a).  High 
incidence of head and neck squamous cell carcinoma in 
patients with Fanconi anemia.  Archives of Otolaryngology 
and Head and  Neck Surgery 129: 106-112. 
Kutler D, Singh B, Satagopan J, Batish SD, Berwick M, 
Giampietro PF, Hanenberg H, Auerbach AD. (2003b).  A 
20-year perspective on the International Fanconi Anemia 
Registry (IFAR).  Blood 101: 1249-56.
Lai C, K. Jeng, K. Machida, Cheng Y, Lai M (2008). Hepatitis 
C virus NS3/4A protein interacts with ATM, impairs DNA 
repair and enhances sensitivity to ionizing radiation.  Virol-
ogy 370: 295-309.
Lakhani  SR (1999).  The pathology of familial breast cancer. 
Morphological aspects. Breast Cancer Research http://
breast-cancer-research.com/vol1no1/27oct99/review/2
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Ander-
son TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, 
Storfer-Isser A, Smyth E, et al. (1998)  Multifactorial analy-
sis of differences between sporadic breast cancers and 
cancers involving BRCA1 and BRCA2 mutations. J. Natl 
Cancer Inst. 90: 1138-1145.
Lee Y, A. Miron, R. Drapkin, et al (2007).  A candidate pre-
cursor to serous carcinoma that originates in the distal 
fallopian tube.  J. Pathol. 211: 26-35.
Lembo D, Donalisio M, Cornaglia M, Azzimonti B, Demur-
tas A, Landolfo S. (2006).Effect of high-risk human papil-
lomavirus oncoproteins on p53R2 gene expression after 
DNA damage. Virus Res. 122(1-2):189-93.
Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, 
Rose DW, Fu XD, Glass CK, Rosenfeld MG (2009). Nuclear 
receptor-induced chromosomal proximity and DNA 
breaks underlie specific translocations in cancer.  Cell 139: 
1069-83.
Liu J, Poiley J, Devetten M, Kajigaya S, Walsh C (1996).  The 
Fanconi anemia complementation group C gene (FAC) sup-
presses transformation of mutant fibroblasts by the SV40 
virus.  Biochemical and Biophysical Res. Communications  
223: 685-690. 
Machado AM, Figueiredo C, Touati E, Máximo V, Sousa S, 
Michel V, Carneiro F, Nielsen FC, Seruca R, Rasmussen LJ. 
(2009) Helicobacter pylori infection induces genetic insta-
bility of nuclear and mitochondrial DNA in gastric cells. 
Clin Cancer Res. 15(9):2995-3002.
Machida K, Cheng K, Lai C-K, Jeng K, Sung V, Lai M (2006). 
Hepatitis C virus triggers mitochondrial permeability 
transition with production of reactive oxygen species, lead-
ing to DNA damage and STAT3 activation.  J. Virology 80: 
7199-7207.
Marietta C, Thompson LH, Lamerdin JE, Brooks PJ. (2009).  
Acetaldehyde stimulates FANCD2 monoubiquitination, 
H2AX phosphorylation, and BRCA1 phosphorylation in 
human cells in vitro: implications for alcohol-related car-
cinogenesis. Mutat Res. 664(1-2):77-83. 
Matsumoto N, Yoshida T, Okayasu I (2003). High Epithelial 
and Stromal Genetic Instability of Chromosome 17 in 
Ulcerative Colitis-associated Carcinogenesis. Cancer res 
63: 6158–6161
McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, 
21
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, et al. 
(2007). Reproductive risk factors for ovarian cancer in car-
riers of BRCA1 or BRCA2 mutations: a case-control study.  
Lancet Oncol. 8: 26–34.  
McGuire V, Felberg A, Mills M, Ostrow KL, DiCioccio R, 
John EM, West DW, Whittemore AS. (2004).  Relation of 
contraceptive and reproductive history to ovarian cancer 
risk in carriers and noncarriers of BRCA1 gene mutations.  
Amer.  J. Epidemiology 160: 613-8.
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup 
DF (1999). Improving the quality of reports of meta-analy-
ses of randomised controlled trials: The QUORUM state-
ment.  Lancet  354: 1896-1900. 
Nakano T, Katafuchi A, Matsubara M, Terato H, Tsuboi T, 
Masuda T, Tatsumoto T, Pack SP, Makino K, Croteau DL, Van 
Houten B, Iijima K, Tauchi H, Ide H (2009). Homologous 
recombination but not nucleotide excision repair plays 
a pivotal role in tolerance to DNA-protein crosslinks in 
mammalian cells.  J. Biol. Chem. 284: 27065-76.
Narod S, Sun P, Ghadirian P, et al. (2001). Tubal ligation and 
risk of ovarian cancer in carriers of BRCA1 or BRCA2 
mutations: a case-control study.  Lancet 357:1467–70.
Olsen JH, Hahnemann JM, Børresen-Dale AL, Tretli S, 
Kleinerman R, Sankila R, Hammarström L, Robsahm TE, 
Kääriäinen H, Bregård A, Brøndum-Nielsen K, Yuen J, Tucker 
M (2005).  Breast and other cancers in 1445 blood rela-
tives of 75 Nordic patients with ataxia-telangiectasia.  Brit. 
J. Cancer 93: 260-5. 
Pace P, mosedale G. Hodskinson M, Rosado I, Sivrasubra-
manian M, Patel K.  Ku70 Corrupts DNA Repair in the 
Absence of the Fanconi Anemia Pathway (2010) Science 
329: 219-223.
Park S, Chan P, Seraj I, King A (1999). Denaturing gradient 
gel electrophoresis screening of the BRCA1 gene in cells 
from precancerous cervical lesions.   J. Reproductive Med. 
44: 575-80. 
Rebbeck T, Kauff N, Domchek S (2009).  Meta-analysis of 
risk reduction estimates associated with risk-reducing 
salpingooophorectomy in BRCA1 or BRCA2 mutation car-
riers.  J. Natl Cancer Inst. 101: 80 – 87. 
Rosen EM, Fan S, Ma Y. (2006). BRCA1 regulation of tran-
scription.  Cancer Lett. 236(2):175-85. 
Rosenberg P, Greene M, Alter B (2003).  Cancer incidence 
in persons with Fanconi anemia.  Blood 101: 822-826. 
Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustac-
chi E. (1994).  Abnormal lymphokine production: a novel 
feature of the genetic disease Fanconi anemia. II. In vitro 
and in vivo spontaneous overproduction of tumor necrosis 
factor alpha.  Blood 83: 1216–1225.
Rutter J, Wacholder S, Chetrit A, et al. (2003). Gyneco-
logic surgeries and risk of ovarian cancer in women with 
BRCA1 and BRCA2 Ashkenazi founder mutations: an 
Israeli population-based case-control study.  J. Natl Cancer 
Inst. 95: 1072–8. 
Saito H, Hammond AT, Moses RE (1993). Hypersensitivity 
to oxygen is a uniform and secondary defect in Fanconi 
anemia cells.  Mutat Res.  294:255-62.
Sawa T, Ohshima H (2006). Nitrative DNA damage in 
inflammation and its possible role in carcinogenesis.  Nitric 
Oxide 14(2):91-100.
Scully R, Livingston DM. (2000) In search of the tumour-
suppressor functions of BRCA1 and BRCA2. Nature. 
408(6811):429-32.
Sejas DP, Rani R, Qiu Y, Zhang X, Fagerlie SR, Nakano H, 
Williams DA, Pang Q (2007). Inflammatory reactive oxy-
gens species-mediated hematopoietic suppression in Fancc-
deficient mice.  J. Immunol: 178, 5277-5287.
Siskind, V., Green, A., Bain, C., Purdie, D (2000). Beyond 
ovulation: oral contraceptives and epithelial ovarian cancer. 
Epidemiology 11: 106–110.
Skomedal H, Helland A, Kristensen G, Holm R, Børresen-
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
Dale A. (1999).  Allelic imbalance at chromosome region 
11q23 in cervical carcinomas.  Eur. J. Cancer 35: 659-63. 
Smoot DT, Elliott TB, Verspaget HW, Jones D, Allen CR, 
Vernon KG, Bremner T, Kidd LC, Kim KS, Groupman JD, 
Ashktorab H (2000). Influence of Helicobacter pylori on 
reactive oxygen-induced gastric epithelial cell injury. Car-
cinogenesis. 21(11):2091-5.
Suhasini A, Sommers J, Mason A, Voloshin O, Camerini-Ot-
ero R, Wold M. Brosh R, Jr. (2009). FANCJ helicase uniquely 
senses oxidative base damage in either strand of duplex 
DNA and is stimulated by replication protein A to unwind 
the damaged DNA substrate in a strand-specific manner.  J. 
Biol. Chem. 284: 18458–18470. 
Swift M, Sholman L, Perry M, Chase C, (1976). Malignant 
neoplasms in the families of patients with ataxia-telangi-
ectasia.  Cancer Res. 36: 209-15. 
Takkouche B, Regueira-Méndez C, Etminan M (2008). 
Breast cancer and use of nonsteroidal anti-inflammatory 
drugs: a meta-analysis.  J. Natl Cancer Inst. 100: 1439-47.
The Breast Cancer Linkage Consortium (1999).  Cancer 
risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91: 
1310-1316. 
Thompson D, Easton D, the Breast Cancer Linkage Con-
sortium (2002). Cancer Incidence in BRCA1 mutation 
carriers.  J. Natl. Cancer Inst. 94:1358-1365.
van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao 
M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, 
Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Ber-
nards R, Friend SH (2002). Gene expression profiling pre-
dicts clinical outcome of breast cancer.  Nature 415: 530-6.
Venkitaraman A (2003).  A growing network of cancer-
susceptibility genes.  N. Engl.  J. Med. 348: 1917-9, 
Vogelstein B, Kinzler K. (2004).  Cancer genes and the 
pathways they control.  Nature Medicine 10: 789-799.
Wagner J,  Tolar J, Levran O, Scholl T, Deffenbaugh A, Sa-
tagopan J, Ben-Porat L, Mah K, Batish S, Kutler D, MacMillan 
M, Hanenberg H, Auerbach A. (2004) Germline mutations 
in BRCA2: shared genetic susceptibility to breast cancer, 
early onset leukemia, and Fanconi anemia  Blood. 103:3226-
3229
Wang-Johanning F, Radvanyi L, Rycaj K, Plummer JB, Yan P, 
Sastry KJ, Piyathilake CJ, Hunt KK, Johanning GL. (2008) 
Human endogenous retrovirus K triggers an antigen-specif-
ic immune response in breast cancer patients. Cancer Res. 
68: 5869-77.  
Wang SS, Bratti MC, Rodríguez AC, Herrero R, Burk RD, 
Porras C, González P, Sherman ME, Wacholder S, Lan ZE, 
Schiffman M, Chanock SJ, Hildesheim A (2009).  Common 
variants in immune and DNA repair genes and risk for hu-
man papillomavirus persistence and progression to cervical 
cancer. J Infect Dis. 199(1):20-30.
Ward A, Olive P, Burr A, Rosin M (1994). Response of fibro-
blast cultures from ataxia-telangiectasia patients to reactive 
oxygen species generated during inflammatory reactions. 
Environ. Molec. Mutagenesis 24: 103-11.
Ward A and  Rosin M (1993).  A protective effect of chro-
mosome 11 against DNA damage by TPA activated neutro-
phils but not TPA acting alone.  Carcinogenesis 15: 2851-7.
Weiss JM, Goode EL, Ladiges WC, Ulrich CM. (2005).  Poly-
morphic variation in hOGG1 and risk of cancer: a review 
of the functional and epidemiologic literature.  Mol Car-
cinog. 2005 Mar;42(3):127-41.
Welcsh PL, King MC. (2001). BRCA1 and BRCA2 and the 
genetics of breast and ovarian cancer. Hum Mol Genet. 
10(7):705-13.
Wernli K, Newcomb P, Hampton J, Trentham-Dietz A, Egan 
K.  (2008).  Inverse association of NSAID use and ovar-
ian cancer in relation to oral contraceptive use and parity.  
Brit. J. Cancer 98:1781-1783. 
23
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
Westbrook A, Schiestl R (2010) Atm-Deficient Mice Exhibit 
Increased Sensitivity to Dextran Sulfate Sodium–Induced 
Colitis Characterized by Elevated DNA Damage and Per-
sistent Immune Activation Cancer Res  70:1875-1884.
Whitby M (2010).  The FANCM family of DNA  helicases / 
translocases. DNA Repair 9: 224–236.
Wolff L, Koller R, Davidson W. (1991) Acute myeloid leuke-
mia induction by amphotropic  murine retrovirus (4070A): 
clonal integrations involve c-myb in some but not all leuke-
mias.. J. Virol. 65(7):3607-3616.
Woodman CB, Collins SI, Young LS. (2007). The natural his-
tory of cervical HPV infection: unresolved issues.  Nat Rev 
Cancer. 7(1):11-22
Yim EK, Lee KH, Myeong J, Tong SY, Um SJ, Park JS. (2007) 
Novel interaction between HPV E6 and BARD1 (BRCA1-
associated ring domain 1) and its biologic roles. DNA Cell 
Biol. 26(10):753-61.
Zanier R,  Briot D, Dugas du Villard J, Sarasin A, Rosselli F 
(2004)  Fanconi anemia C gene product regulates expres-
sion of genes involved in differentiation and inflammation.  
Oncogene 23; 5004-13.
Zhou B,  Elledge S (2002) The BRCA1 suppressor 
hypothesis:An explanation for the tissue-specific tumor 
development in BRCA1 patients Cancer Cell 1:129-132.
Zhou X, Han S, Wang S, Chen X, Dong J, Shi X, Xia Y, Wang 
X, Hu Z, Shen H. (2009). Polymorphisms in HPV E6/E7 
protein interacted genes and risk of cervical cancer in Chi-
nese women: a case-control analysis. Gynecol Oncol. 2009 
Aug;114(2):327-31.
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
88
1.
1 
: P
os
te
d 
10
 S
ep
 2
01
0
